Indication

Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity

This clinical indication refers to chronic weight reduction and maintenance in adults who are medically classified as overweight—specifically possessing a body mass index (BMI) of 27 to 29 kg/m²—and who have at least one adiposity-related medical complication. Read more about Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity

44 drugs 34 manufacturers

Advertisement

Drugs that treat it

Common Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity therapies.

Showing 28–36 of 44 drugs

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
EPIC PHARMA LLC

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
A-S MEDICATION

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
DIRECT RX

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
PROFICIENT RX L

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
BRYANT RANCH PR

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
ELITE LABORATOR

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
PRECISION DOSE

PHENTERMINE HCL

AMPHETAMINES/ANOREXIANTS/STIMULANTS·WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER)·+1
MARTEK PHARMACA
Filter & compare in the drug finder →Opens the drug finder with Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity.

This clinical indication refers to chronic weight reduction and maintenance in adults who are medically classified as overweight—specifically possessing a body mass index (BMI) of 27 to 29 kg/m²—and who have at least one adiposity-related medical complication.

It targets individuals whose excess adiposity drives systemic metabolic and biomechanical dysfunction across cardiovascular, endocrine, and respiratory systems.

Defining pathophysiologic features involve dysfunctional adipose tissue signaling, chronic low-grade inflammation, and insulin resistance that precipitate or exacerbate conditions such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.

Pharmacotherapy is directed at achieving sustained adipose mass reduction to mitigate cardiometabolic risk and arrest progression toward overt obesity-associated organ damage.

Personalize your experience

Follow Weight loss management for overweight patient with bmi 27 to 29 and weight-related comorbidity and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it